Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex-deficient cancers.

Chromatin regulating factors are largely divided into 2 groups: chromatin remodeling complexes and histone modifying factors (Figure 3 ). Chromatin remodeling complexes use the energy of ATP hydrolysis and maintain chromatin structure by opening or closing chromatin through sliding, ejecting, repositioning, or inserting nucleosomes, which are histone octamers composed of histones H2A, H2B, H3, and H4. 10 Histone modifying factors maintain the interaction between DNA and histones through histone methylation/demethylation, acetylation/deacetylation, and ubiquitylation/deubiquitylation. These chromatin regulating factors control binding of various functional proteins, such as transcription factors, DNA replication factors, DNA repair factors, and chromosome segregation factors to chromatin by remodeling and modifying chromatin structure. Therefore, chromatin regulating factors contribute to the regulation of transcription, DNA repair, DNA replication, and chromosomal segregation. Role of chromatin regulators

Recent advances in genome‐wide sequencing technologies have contributed to the identification of most gene mutations associated with cancer. Comprehensive genome studies identified mutations in genes involved in chromatin regulation in approximately 50% of cancers. 11 , 12 , 13 , 14 Most of the mutations in chromatin regulating genes are LOF mutations such as deleterious missense mutations, frameshift mutations, and chromosomal deletions. Mutations in SWI/SNF chromatin remodeling genes occur with high frequency in cancer; they are detected in approximately 20% of all cancer patients. 15 , 16 The SWI/SNF chromatin remodeling complex is composed of 15 subunits, and it is classified into 3 complexes comprising different subunits (Figure 4 ): the BRG1/BRM‐associated factor (BAF) complex, the polybromo‐associated BAF (PBAF) complex, and the noncanonical BAF (ncBAF) complex. 17 , 18 The function of the SWI/SNF chromatin remodeling complex relies on the catalytic activities of the SWI/SNF2‐like ATPase and helicase domains. It is composed of accessory subunits harboring chromatin‐binding motifs, such as a bromodomain. Specifically, LOF genetic aberrations of SMARCA4, ARID1A, ARID2, PBRM1, and SMARCB1 are common in various cancers such as lung cancer, ovarian clear cell carcinoma, skin cancer, renal clear cell carcinoma, and rhabdoid tumors, respectively. Gain‐of‐function genetic aberrations of SS18 by fusion of SS18 and SSXs (SSX1, SSX2, or SSX4) are observed in all synovial sarcoma patients. 19 Most SWI/SNF chromatin remodeling genes, except the SS18‐SSX fusion, cause LOF genetic aberrations in cancer. Therefore, the development of therapies based on synthetic lethality would be a promising therapeutic strategy. In this review, we introduce a synthetic lethal therapy strategy for the treatment of cancers with genetic aberrations of SWI/SNF chromatin remodeling genes (Figures 4 and 5 ). Genetic abnormality of SWI/SNF chromatin remodeling components in various cancers Synthetic lethal targets in cancers deficient in the SWI/SNF chromatin remodeling complex. A, Synthetic lethal targets based on targeting the interaction between 2 subunits in the SWI/SNF chromatin remodeling complex. B, Synthetic lethal targets based on targeting the competitor with the SWI/SNF chromatin remodeling complex. C, Synthetic lethal targets based on targeting the function of the SWI/SNF chromatin remodeling complex

ARID1A and PBRM1 are components of different complexes, namely, the BAF complex and PBAF complex, respectively. Therefore, immunotherapies against ARID1A‐deficient cancers and PBRM1‐deficient cancers should be based on different mechanisms. Cancers with a genetic aberration in mismatch repair are characterized by hypermutation frequency and should respond to immune checkpoint inhibition using programmed death‐ligand 1 (PD‐L1) and programmed death‐1 (PD‐1) Abs because of increased antigen presentation. 50 The ARID1A‐containing BAF complex interacts with mismatch repair factors and positively regulates mismatch repair. Therefore, ARID1A‐deficient cancer cells have a high mutation rate because of the deficiency in mismatch repair. 51 Cancer immunotherapy would be a promising strategy for ARID1A‐deficient cancers. In addition to mismatch repair deficiency, the activity of the interferon‐γ signaling pathway modulates the sensitivity to cancer immunotherapy. 52 The PBRM1‐containing PBAF complex functions in the repression of genes involved in promoting interferon‐γ signaling pathway activity. 53 PBRM1‐deficient renal clear cell carcinoma would benefit from cancer immunotherapy because the interferon‐γ signaling pathway is activated in PBRM1‐deficient cancer cells. Cancer immunotherapy is a promising strategy for cancers deficient in the SWI/SNF chromatin remodeling complex. The effect of SWI/SNF chromatin remodeling complex deficiency on the response to chemotherapy using cytotoxic anticancer agents remains unclear. Ovarian clear cell carcinoma has the highest rate of ARID1A mutation among cancers. ARID1A‐deficient ovarian clear cell carcinoma cells are selectively sensitive only to gemcitabine among the standard chemotherapeutic agents for ovarian clear cell carcinoma that are currently available. 54 The first‐line standard chemotherapy for ovarian clear cell carcinoma is combination therapy with paclitaxel and carboplatin. The use of gemcitabine is limited to tumors showing relapse after paclitaxel and carboplatin therapy. However, gemcitabine shows promise for use as a first‐choice agent for optimized therapy in ARID1A‐deficient ovarian clear cell carcinoma in the future.

The SWI/SNF chromatin remodeling complex functions in transcription, DNA repair, DNA replication, and chromosomal segregation. Therefore, cancers deficient in the SWI/SNF chromatin remodeling complex are vulnerable because of the abrogation of these cellular functions (Figure 5 C). Regarding DNA repair, the SWI/SNF chromatin remodeling complex is involved in DNA double‐strand break repair and DNA damage checkpoint regulation. The PARP1 inhibitor olaparib is approved for BRCA1/2‐deficient ovarian and breast cancers, which are deficient in homologous recombination repair, a DNA double‐strand break repair mechanism. In ARID1A‐deficient cancers, which are deficient in homologous recombination‐mediated DNA double‐strand break repair, treatment with a PARP inhibitor causes synthetic lethality. 41 In the SWI/SNF chromatin remodeling complex, the BAF complex is required for chromatin binding of topoisomerase II (TOP2), which is necessary for DNA replication and chromosomal segregation. ARID1A mediates the physical interaction between the BAF complex and TOP2. 42 Thus, TOP2 dysfunction in BAF complex‐deficient tumors, such as ARID1A‐deficient cancers, results in aberrant DNA replication and chromosomal segregation. Based on the abnormality of those cellular functions, BAF complex‐deficient cancer cells are selectively sensitive to inhibitors of the cell cycle regulators cyclin‐dependent kinase (CDK)4/CDK6, the DNA replication checkpoint factor ATR, and the chromosomal segregation factor Aurora kinase A. 43 , 44 , 45 , 46 , 47 The SWI/SNF chromatin remodeling complex is involved in the regulation of several metabolic pathways. The energy supply in cancer cells is derived from ATP generated by the glycolytic pathway. However, SMARCA4‐deficient lung cancer cells depend on energy supplied by the oxidative phosphorylation pathway rather than the glycolytic pathway, and are therefore sensitive to inhibition of oxidative phosphorylation. 48 In addition, the cells are exposed to oxidative stress, such as that caused by reactive oxygen species (ROS), which damage DNA and proteins. Excessive generation of ROS leads to induction of cell death. However, the intracellular antioxidant system can effectively mediate resistance to oxidative stress by suppressing ROS through the antioxidant metabolite glutathione (GSH). Thus, the balance between oxidative stress and the antioxidant metabolite GSH maintains cellular homeostasis. We recently showed that impairment of the GSH metabolic pathway is a vulnerability of ARID1A‐deficient cancer cells. 49 Glutathione is a tripeptide metabolite synthesized from cysteine, glutamate, and glycine. ARID1A positively regulates the transcription of SLC7A11, which encodes a protein required for the maintenance of intracellular cysteine. 49 Deficiency in ARID1A results in SLC7A11 downregulation, which decreases intracellular cysteine. The low basal level of GSH in ARID1A‐deficient cancer cells leads to vulnerability. Inhibition of GSH by the GSH inhibitor APR‐246 or buthionine sulfoximine, an inhibitor of the glutamate cysteine ligase catalytic subunit (which catalyzes the synthesis of GSH), causes excessive increase of ROS and leads to synthetic lethality in ARID1A‐deficient cancer cells. 49 These data indicate that inhibitors of metabolic pathways, such as the oxidative phosphorylation pathway and the GSH metabolic pathway, are promising therapeutic agents for cancers with deficiencies in the SWI/SNF chromatin remodeling complex because of vulnerabilities derived from metabolic pathway deficiencies.

The SWI/SNF chromatin remodeling complex is composed of many subunits, and the encoding genes are frequently mutated in various cancers. Whether an inhibitor of a synthetic lethal target in cancers deficient in one gene could be effective for cancers with a deficiency in another gene, including genes encoding the subunits of the SWI/SNF chromatin remodeling complex, remains unknown. However, because the SWI/SNF chromatin remodeling complex is divided into the BAF, PBAF, and ncBAF complexes, expanding the indications for an inhibitor of a synthetic lethal target might not be simple. Frequently mutated genes tend to be characteristic of different tumor types, such as SMARCA4 in lung adenocarcinoma (10% frequency), ARID1A in ovarian clear cell carcinoma (50% frequency), PBRM1 in renal clear cell carcinoma (40% frequency), and SMARCB1 in rhabdoid tumors (100% frequency). Mutation of each gene is important for carcinogenesis in every tumor type. The mechanism underlying the effect of cancer‐specific gene mutations can be elucidated by determining the functional relationship based on synthetic lethality. ARID1A mutation occurs in the early stage of precancerous endometriosis and clear cell adenofibroma. 55 , 56 In addition, ROS could contribute to cancer transformation by promoting gene mutation or by stimulating cellular signaling. 57 , 58 , 59 , 60 The basal level of ROS increases as a result of a decrease of GSH in ARID1A‐deficient ovarian cancer cells. 49 These findings suggest that ARID1A abrogation is involved in oncogenesis by contributing to a dysregulated balance between ROS and GSH homeostasis. The clinical success rate of therapy based on biomarkers of LOF mutations in SWI/SNF chromatin remodeling genes could be improved by identifying promising drug targets using the concept of synthetic lethality. Many synthetic lethal targets for cancers with SWI/SNF chromatin remodeling complex deficiency have been identified. Inhibitors of these synthetic lethal targets have been developed, many of which are currently under clinical trials or approved for clinical use (Table 1 ). It is expected that these promising drugs will be approved for clinical application in cancers with SWI/SNF chromatin remodeling complex deficiency in the near future. Candidate drugs against synthetic lethal targets in cancers deficient in the SWI/SNF chromatin remodeling complex

Current precision medicine strategies for human cancers target activated proteins such as the tyrosine kinases EGFR, BRAF, and ALK‐fusion; these proteins are activated by gain‐of‐function genetic aberrations including gene mutation, amplification, and fusion (Figure 1 ). 1 , 2 , 3 Activated oncogenes constitute a specific vulnerability of cancer cells. Inhibition of the synthesis or activity of these oncogenes results in cell death, specifically in cells expressing the activated oncogene; the dependence of cells on an oncogene for survival is defined as “oncogene addiction”. 4 Only a fraction of cancers have an activated oncogene, whereas many cancers have other genetic aberrations such as loss‐of‐function (LOF) mutations. Certain LOF gene mutations of tumor suppressor genes confer druggable vulnerabilities on cancer cells. However, because genes with LOF mutations are inactivated, the LOF mutation gene product is not a target for inhibition (Figure 1 ). Harnessing synthetic lethality, such as that based on LOF gene mutations, has emerged as an attractive therapeutic strategy; however, to date, this strategy has not been widely successful. Synthetic lethality is defined by an interdependent relationship between 2 genes, which means that simultaneous loss of 2 genes, but not loss of either gene alone, leads to cell death (Figure 1 ). 5 , 6 , 7 Cancer cells harboring a LOF gene mutation would therefore be vulnerable to inhibition of the synthetic lethal target. Precision medicine based on cancer mutations. PARP, poly(ADP‐ribose) polymerase In this review, “synthetic lethal therapy” is defined as cancer therapy based on synthetic lethality. This strategy is based on the assumption that a cancer patient has a LOF mutation of “gene A” and gene A is synthetic lethal with gene B (Figure 2 ). In cancer cells, gene A is the LOF gene, and therapy with an inhibitor of B causes cell death based on synthetic lethality because of the simultaneous suppression of the function of both A and B. In normal cells, gene A is normal; therefore, inhibition of gene B does not affect the survival of normal cells. Synthetic lethal therapy is expected to have high selectivity against cancer cells and few side‐effects. Thus, the identification of cancer vulnerabilities associated with LOF gene mutations should lead to marked improvements in cancer therapy, as epitomized by the success of poly(ADP‐ribose) polymerase (PARP)1‐targeted therapy against hereditary breast and ovarian cancers harboring LOF mutations of the BRCA1 and BRCA2 genes. 8 , 9 Synthetic lethal therapy: cancer therapy based on synthetic lethality

The authors have no conflict of interest to declare.